Now, investing in pharmaceutical companies, one discovers, is a bit like backing a particularly enthusiastic but somewhat unpredictable racehorse. A prodigious amount of time and capital is poured into the development of these potions and pills, years stretching into decades, and a truly alarming sum of money – upwards of $2.6 billion, if you please – vanishes into test tubes and research labs. And yet, the odds, one might say, are stacked against success. A mere 8% of these hopeful concoctions actually make it to market, which is a dashedly low figure, wouldn’t you agree?
Even should a drug triumphantly emerge, its moment in the sun is often fleeting. A patent, nominally lasting twenty years, is largely consumed by the development process itself. The actual period of exclusive benefit, the time when one can reap the rewards of ingenuity, is frequently limited to a mere decade or so. One recalls the case of Pfizer, whose stock experienced a rather giddy ascent around the year 2000, thanks to a certain vaccine. However, as demand waned, so too did the stock’s fortunes, plummeting in 2023 and remaining stubbornly unenthusiastic since. A cautionary tale, to be sure.
Which brings me, with a degree of purposeful meandering, to Eli Lilly (LLY +0.21%). When one considers a venture of this sort, the pipeline, the future stream of potential blockbusters, is paramount. And it is here that Lilly shines, positively sparkles, if I may say so. I would, without a moment’s hesitation, purchase shares and hold them for the long term. A sound investment, a positively ripping good idea, what?
Lilly’s Pipeline: A Most Promising Collection
Last week, the company announced the acquisition of Orna Therapeutics for a cool $2.4 billion. This firm is developing rather ingenious drugs that manipulate genes and cells within the patient, a decidedly clever bit of engineering, avoiding the messy business of laboratory tinkering. Should this ORN-252 reach the market, it could be the next sensation, a veritable bonanza for investors.
And as if that weren’t enough, Lilly further announced a $350 million collaboration with a Chinese biotechnology company, focusing on immune disorders and cancer. And in January, another billion-dollar deal with a German firm to develop gene therapies for hearing loss. A flurry of activity, wouldn’t you say? A positively energetic display of entrepreneurial spirit!
Oh, and let us not forget that Lilly currently boasts the best-selling drug on the planet: tirzepatide. This remarkable substance addresses both type 2 diabetes and obesity, dethroning Merck’s Keytruda, a feat not to be sneezed at. It’s marketed as Mounjaro for diabetes and Zepbound for weight loss, a clever marketing ploy, if I may say so.
Lilly shares have soared over 400% in the past five years, leaving the S&P 500 (with its comparatively modest 73% climb) rather in the dust. And with a market capitalization approaching $936 billion, the company is rapidly joining the elite $1 trillion club, a select gathering of just twelve public companies. A most impressive achievement, wouldn’t you agree? A thoroughly ripping success!
Read More
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Wuchang Fallen Feathers Save File Location on PC
- Gold Rate Forecast
- Brown Dust 2 Mirror Wars (PvP) Tier List – July 2025
- All weapons in Wuchang Fallen Feathers
- Where to Change Hair Color in Where Winds Meet
- Top 15 Celebrities in Music Videos
- Here Are the Best TV Shows to Stream this Weekend on Paramount+, Including ‘48 Hours’
- Top 15 Movie Black-Haired Beauties, Ranked
- Best Video Games Based On Tabletop Games
2026-02-17 20:24